vs
Side-by-side financial comparison of Boxlight Corp (BOXL) and Journey Medical Corp (DERM). Click either name above to swap in a different company.
Boxlight Corp is the larger business by last-quarter revenue ($29.3M vs $16.1M, roughly 1.8× Journey Medical Corp). Journey Medical Corp runs the higher net margin — -7.8% vs -21.1%, a 13.3% gap on every dollar of revenue. On growth, Journey Medical Corp posted the faster year-over-year revenue change (27.3% vs -19.2%). Over the past eight quarters, Journey Medical Corp's revenue compounded faster (11.0% CAGR vs -23.1%).
Boxlight Corp is a global provider of interactive technology solutions, including interactive flat panel displays, projectors, collaborative software, and classroom technology accessories. It primarily serves K-12 and higher education institutions, as well as corporate and government customers across North America, Europe, and Asia Pacific, focusing on enhancing learning and work collaboration efficiency.
Journey Medical Corp is a commercial-stage biopharmaceutical company specializing in dermatology treatments. It develops, manufactures and markets prescription and over-the-counter products addressing acne, atopic dermatitis, fungal skin infections and other dermal conditions, primarily serving healthcare providers and patients across the United States.
BOXL vs DERM — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $29.3M | $16.1M |
| Net Profit | $-6.2M | $-1.2M |
| Gross Margin | 29.1% | — |
| Operating Margin | -13.4% | -2.8% |
| Net Margin | -21.1% | -7.8% |
| Revenue YoY | -19.2% | 27.3% |
| Net Profit YoY | -102.0% | -182.0% |
| EPS (diluted) | $-1.88 | $-0.04 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $16.1M | ||
| Q3 25 | $29.3M | $17.0M | ||
| Q2 25 | $30.9M | $15.0M | ||
| Q1 25 | — | $13.1M | ||
| Q4 24 | $24.0M | $12.6M | ||
| Q3 24 | $36.3M | $14.6M | ||
| Q2 24 | $38.5M | $14.9M | ||
| Q1 24 | $37.1M | $13.0M |
| Q4 25 | — | $-1.2M | ||
| Q3 25 | $-6.2M | $-2.3M | ||
| Q2 25 | $-4.7M | $-3.8M | ||
| Q1 25 | — | $-4.1M | ||
| Q4 24 | $-16.7M | $1.5M | ||
| Q3 24 | $-3.1M | $-2.4M | ||
| Q2 24 | $-1.5M | $-3.4M | ||
| Q1 24 | $-7.1M | $-10.4M |
| Q4 25 | — | — | ||
| Q3 25 | 29.1% | — | ||
| Q2 25 | 35.0% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 30.6% | 82.3% | ||
| Q3 24 | 33.8% | 63.9% | ||
| Q2 24 | 37.7% | 56.0% | ||
| Q1 24 | 34.5% | 47.7% |
| Q4 25 | — | -2.8% | ||
| Q3 25 | -13.4% | -9.0% | ||
| Q2 25 | -12.7% | -19.2% | ||
| Q1 25 | — | -25.3% | ||
| Q4 24 | -67.6% | 17.7% | ||
| Q3 24 | -2.4% | -19.8% | ||
| Q2 24 | 3.2% | -19.7% | ||
| Q1 24 | -9.7% | -77.4% |
| Q4 25 | — | -7.8% | ||
| Q3 25 | -21.1% | -13.6% | ||
| Q2 25 | -15.3% | -25.3% | ||
| Q1 25 | — | -31.0% | ||
| Q4 24 | -69.6% | 12.1% | ||
| Q3 24 | -8.4% | -16.3% | ||
| Q2 24 | -3.8% | -22.6% | ||
| Q1 24 | -19.1% | -80.1% |
| Q4 25 | — | $-0.04 | ||
| Q3 25 | $-1.88 | $-0.09 | ||
| Q2 25 | $-1.53 | $-0.16 | ||
| Q1 25 | — | $-0.18 | ||
| Q4 24 | $-87.29 | $0.10 | ||
| Q3 24 | $-1.72 | $-0.12 | ||
| Q2 24 | $-0.92 | $-0.17 | ||
| Q1 24 | $-0.76 | $-0.53 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $11.8M | $24.1M |
| Total DebtLower is stronger | $36.7M | $25.3M |
| Stockholders' EquityBook value | $-19.5M | $31.9M |
| Total Assets | $99.6M | $94.6M |
| Debt / EquityLower = less leverage | — | 0.79× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $24.1M | ||
| Q3 25 | $11.8M | $24.9M | ||
| Q2 25 | $7.6M | $20.3M | ||
| Q1 25 | — | $21.1M | ||
| Q4 24 | $8.0M | $20.3M | ||
| Q3 24 | $10.5M | $22.5M | ||
| Q2 24 | $7.5M | $23.9M | ||
| Q1 24 | $11.8M | $24.1M |
| Q4 25 | — | $25.3M | ||
| Q3 25 | $36.7M | $25.2M | ||
| Q2 25 | $39.0M | $25.1M | ||
| Q1 25 | — | $25.0M | ||
| Q4 24 | $37.1M | $24.9M | ||
| Q3 24 | $38.8M | $19.8M | ||
| Q2 24 | $40.3M | $19.7M | ||
| Q1 24 | $38.5M | $14.7M |
| Q4 25 | — | $31.9M | ||
| Q3 25 | $-19.5M | $25.9M | ||
| Q2 25 | $-20.6M | $19.2M | ||
| Q1 25 | — | $21.5M | ||
| Q4 24 | $-12.9M | $20.1M | ||
| Q3 24 | $6.5M | $10.9M | ||
| Q2 24 | $7.5M | $11.3M | ||
| Q1 24 | $9.1M | $13.0M |
| Q4 25 | — | $94.6M | ||
| Q3 25 | $99.6M | $85.2M | ||
| Q2 25 | $99.2M | $81.2M | ||
| Q1 25 | — | $85.0M | ||
| Q4 24 | $115.3M | $80.2M | ||
| Q3 24 | $142.9M | $64.0M | ||
| Q2 24 | $141.3M | $65.2M | ||
| Q1 24 | $142.4M | $66.6M |
| Q4 25 | — | 0.79× | ||
| Q3 25 | — | 0.97× | ||
| Q2 25 | — | 1.30× | ||
| Q1 25 | — | 1.16× | ||
| Q4 24 | — | 1.24× | ||
| Q3 24 | 5.93× | 1.81× | ||
| Q2 24 | 5.38× | 1.75× | ||
| Q1 24 | 4.23× | 1.13× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $1.3M | $-6.3M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-6.3M | ||
| Q3 25 | $1.3M | $-2.4M | ||
| Q2 25 | — | $-942.0K | ||
| Q1 25 | — | $-2.8M | ||
| Q4 24 | $1.6M | $2.2M | ||
| Q3 24 | $5.2M | $-1.2M | ||
| Q2 24 | $-5.4M | $-5.2M | ||
| Q1 24 | $-1.9M | $-5.0M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 1.46× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BOXL
| Products | $27.4M | 93% |
| Services | $2.0M | 7% |
DERM
| Qbrexza | $5.5M | 35% |
| Emrosi | $5.0M | 31% |
| Accutane | $3.1M | 19% |
| Other | $2.5M | 15% |
